• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ADXS

    Advaxis, Inc.

    Subscribe to $ADXS
    $ADXS
    Major Pharmaceuticals
    Health Care

    Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

    IPO Year: n/a

    Exchange: NASDAQ

    Website: advaxis.com

    Recent Analyst Ratings for Advaxis, Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Advaxis, Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Advaxis, Inc.

      15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      5/9/24 4:05:37 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)

      10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/26/24 5:03:01 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)

      8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/19/24 7:50:34 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by Advaxis, Inc.

      10-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/16/24 4:11:03 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:34:50 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:34:22 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:33:49 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:33:22 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:32:50 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Advaxis, Inc.

      S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/15/24 4:32:18 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    Advaxis, Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      3/6/24 7:13:01 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      2/12/24 2:16:21 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/21/23 9:04:41 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • New insider Cabilly Yuval claimed ownership of 1,298,639 shares (SEC Form 3)

      3 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/8/23 4:01:18 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Golan Roy (Amendment)

      3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/3/23 11:46:10 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Orbach Pini (Amendment)

      3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/3/23 11:45:26 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Martell Bridget A (Amendment)

      3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/3/23 11:43:16 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Israel Biotech Fund I, L.P. bought 1,317,716 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      10/31/23 7:08:02 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Amoon Growth Fund Limited Partnership disposed of 0 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      10/23/23 6:43:18 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Israel Biotech Fund I, L.P. (Amendment)

      4/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      9/29/23 6:13:52 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    Advaxis, Inc. Leadership Updates

    Live Leadership Updates

    See more
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

      SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar

      4/2/21 7:33:00 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care